Allostere, Inc. is a San Diego-based biotech company focused on the discovery and development of novel allosteric drugs to meet the growing demand for selective nontoxic therapies.

Our primary mission is to develop first-in-class mechanistically novel therapeutics for the treatment of metastatic cancer.

The company’s current development pipeline focuses on the oncogenes and key regulators in sumoylation, neddylation, ubiquitination, PI3 kinase cancer pathways and metastatic mechanisms